Renal cell carcinoma is a common type of human cancer that accounts for 3% of adult malignancies worldwide. 1 Although therapeutic outcomes have recently improved for surgical treatment of early RCC, it remains one of the world's leading causes of cancer-related death. 2 The prognosis of advanced RCC is poor in part because RCC is often resistant to traditional therapies such as radiation therapy and chemotherapy. Epidermal growth factor receptor-tyrosine kinase inhibitors and immunocheckpoint inhibitors targeting PD-1 or its ligand PD-L1 showed promising therapeutic efficacy in advanced RCC. [3] [4] [5] [6] [7] Recent reports showed that the expression of EGFR and PD-L1 is a poor prognostic factor in RCC. 6-8 Prognostic biomarkers are important in the guidance of therapeutic options and
surveillance strategies. 9 Tumor-node-metastasis staging, nuclear grade, and vein invasion have been the most reliable prognostic factors in RCC. 9, 10 However, their predictive accuracy remains limited due to individual variations. Therefore, there is a requirement for identifying new prognostic markers and new potential therapeutic targets in advanced RCC. Cancer stem cells are closely associated with chemotherapy resistance, recurrence, and metastasis. In RCC, CSCs have been reported as useful prognostic markers. 9 Claspin is a nuclear protein related to DNA replication and damage response and is an important regulator for the S-phase checkpoint. 11 Phosphorylated claspin interacts with Chk1 to promote its activation by ATR-dependent phosphorylation. [11] [12] [13] Downregulation of claspin, and ATR and Chk1, greatly reduces cell survival and promotes alterations in cell cycle checkpoints and DNA repair systems. 12 These alterations could lead to genomic instability that triggers cancer development. [14] [15] [16] However, it has been reported that overexpression of claspin contributes to tumor proliferation in several human solid tumors, such as colon, lung, bladder, breast, ovarian, and cervical cancers. [16] [17] [18] [19] Previously, we identified upregulation of the CLSPN gene in spheroid body-forming GC cell lines. 20 We also reported that overexpression of claspin is found in 47% of GC cases and is associated with tumor progression in GC. 20 Therefore, depending on the circumstances, claspin plays an ambivalent function of tumor suppression and promotion. To our knowledge, however, detailed function and expression profiles of the CLSPN gene in RCC have not previously been analyzed.
The present study is the first detailed analysis of claspin expression in RCC including its clinicopathological significance and biological function. To clarify the pattern of expression and localization of claspin in RCC, we undertook immunohistochemical analysis of surgically resected RCC samples and investigated the association between claspin expression and various clinicopathological characteristics. We also analyzed the effect of inhibiting claspin expression on cell growth of RCC cells. In addition, we investigated the relationship between claspin expression and representative cancer-related molecules, including CSC markers, in RCC.
| MATERIAL S AND ME THODS

| Tissue samples and cell lines
In this retrospective study, 95 primary tumors were collected from patients diagnosed as having RCC who underwent curative resection surgery at Hiroshima University Hospital (Hiroshima, Japan). All samples were obtained with patient consent, and the present study was approved by the Ethical Committee for Human Genome Research of Hiroshima University. However, written informed consent was not obtained; thus, for strict privacy protection, all identifying information associated with the samples was removed before the analysis.
Only patients without preoperative radiotherapy or chemotherapy were enrolled in the study. The study cohort included 70 men and 25 women. Postoperative follow-up was scheduled every 1, 2, or 3 months during the first 2 years after surgery and every 6 months thereafter, unless more frequent follow-up was deemed necessary.
Chest X-rays, chest computed tomography scans, and serum chemistry analyses were undertaken at every follow-up visit. Recurrence was evaluated from the patient records at Hiroshima University Hospital. Patients were followed by their physician until the patient's death or date of the last documented contact. Tumor staging was evaluated according to the TNM stage grouping system.
Human RCC-derived cell lines ACHN, Caki-1, and 786 were purchased from the Japanese Collection of Research Bioresources Cell Bank (Osaka, Japan). All cell lines were maintained in RPMI-1640 (Nissui Pharmaceutical) containing 10% FBS (Whittaker) in a humidified atmosphere of 5% CO 2 and 95% air at 37°C.
| Immunohistochemistry
We used archival formalin-fixed, paraffin-embedded tissues from 95 Dako Cytomation) and anti-PD-L1 Ab (ab205921, 1:300, clone 28-8;
Abcam) for 1 hour at room temperature, followed by incubation with Envision+ anti-mouse peroxidase for 1 hour. The sections were incubated with DAB Substrate-Chromogen Solution (Dako Cytomation) for 5 minutes for color reaction and then counterstained with 0.1% hematoxylin. Negative controls were created by omission of the primary Ab.
When more than 10% of tumor cells were stained, immunostaining was considered positive for claspin (according to the median cut-off values rounded to the nearest 10%). Using these definitions, 2 observers (GK and KS) without knowledge of the clinical and pathologic parameters or patient outcomes, independently reviewed immunoreactivity in each specimen. If there were either slight discrepancies between 2 sections or interobserver differences, they were resolved by consensus review at a double-headed microscope after independent review.
The expressions of CD44, ALDH1, CD133, EGFR, HER2, and PD-L1
were scored in all tumors as positive or negative. When more than 10% of tumor cells showed membranous staining, the immunostaining was considered positive. Scoring of ALDH1 was according to the intensity of Ab staining (0, no staining; 1+, weak staining; 2+, moderate staining; 3+, intense staining). All cases with Ab staining of 3+ or 2+ were defined as ALDH1 positive. The expression of PD-L1 in RCC has been reported in several studies, and various criteria have already existed. Thus, we decided that the immunostaining of PD-L1 was considered positive according to median cut-off values rounded off to the nearest 5%.
| Western blot analysis
Tumor cells were lysed for western blotting as described previously. 21 The lysates (40 μg) were solubilized in Laemmli sample buffer by boiling and then subjected to 10% SDS-PAGE and electrotransferred onto a nitrocellulose filter. The filter was incubated with the primary Ab against claspin. The claspin Ab was a polyclonal Ab that had been raised in our laboratory, and its specificity has been characterized in detail. Peroxidase-conjugated anti-mouse IgG was used in the secondary reaction. Immunocomplexes were visualized with an ECL Western Blot Detection System (Amersham Biosciences).
β-Actin antibody (Sigma Chemical) was also used as a loading control.
| RNA interference
To knock down endogenous claspin, RNAi was carried out as described previously. 22 Small interference oligonucleotides for claspin and a negative control were purchased from Invitrogen. Transfection was carried out using Lipofectamine RNAiMAX (Invitrogen) according to the manufacturer's protocol. Briefly, 60 pmol siRNA and 10 μL Lipofectamine RNAiMAX were mixed in 1 mL RPMI medium (10 nmol/L final siRNA concentration). After 20 minutes of incubation, the mixture was added to the cells, and these were plated on dishes for each assay. The cells were analyzed at 48 hours after transfection in all experiments.
| Cell growth assays
An MTT assay was carried out to examine cell growth. The cells were seeded at a density of 4000 cells/well in 96-well plates. Cell growth was monitored after 1, 2, and 4 days. We undertook 3 different experiments and calculated the mean and SD in each of the MTT assays and the modified Boyden chamber assays.
| Statistical analysis
Correlations between the clinicopathological parameters and claspin expression were analyzed using Fisher's exact test. Kaplan-Meier survival curves were constructed for claspin-positive and claspinnegative patients, and the survival rates of the 2 groups were compared. Differences between the survival curves were tested for statistical significance by log-rank test. Univariate and multivariate Cox regression analyses were used to evaluate the associations between clinical covariates and survival as described previously. 23 
| RE SULTS
| Expression analysis of claspin in RCC
Claspin expression was detected in 45 (47%) of 95 RCCs by immunohistochemistry, and it showed nuclear staining in tumor cells ( Figure 1A) .
In high-power fields, claspin staining in the high nuclear grade tumors appeared relatively stronger than that in the low nuclear grade tumors ( Figure 1B,C) . In the nonneoplastic kidney, the staining of claspin was either weak or absent in epithelial and stromal cells ( Figure 1D ). Next, we analyzed the relationship between claspin expression and various clinicopathological characteristics. Claspin expression was associated with higher T grade (P = .0251), tumor stage (P = .0211), nuclear grade (P = .0105), and vein invasion (P = .0347) in claspin-positive than in claspin-negative RCC cases ( 
| Relationship between claspin expression and prognosis in RCC
We undertook a Kaplan-Meier analysis to investigate the association between claspin expression and patient prognosis. Claspin expression was significantly associated with a poorer prognosis (P = .0432, log-rank test; Figure 1E ). We also undertook univariate and multivariate Cox proportional hazards analyses but did not find claspin expression to be an independent prognostic predictor (Table 2 ). Furthermore, the RNA sequencing data from TCGA provided the survival analysis between RCC cases and CLSPN mRNA.
The result showed a tendency for claspin expression to be associated with poor prognosis in RCC patients.
| Effect of claspin downregulation on cell growth activity of RCC cells
We next investigated the effect of claspin inhibition on cell growth on RCC cells using siRNA. Western blot analysis of claspin in 3 RCC cell lines (ACHN, Caki-1, and 786) showed that expression of claspin was detected in all 3 lines (Figure 2A ). We selected ACHN cells for knockdown analysis because the highest claspin expression was detected in these cells. Claspin expression was suppressed by treatment with siRNA2 and siRNA3, as confirmed by western blot analysis ( Figure 2B) . To investigate the possible antiproliferative effects of CLSPN knockdown, we carried out an MTT assay at 4 days after the transfection of siRNA. Cell proliferative ability was significantly reduced in CLSPN knockdown RCC cells compared with negative control siRNA-transfected RCC cells ( Figure 2C ).
| Effect of claspin inhibition on Akt and Erk pathways
To clarify the molecular signaling pathways associated with proliferation activities, we elaborated the phosphorylation of EGFR down- Negative (n = 62) 21 (33) 41
Note: P values were calculated with Fisher's exact test.
Abbreviations: ALDH1, aldehyde dehydrogenase isoform 1; EGFR, epidermal growth factor receptor; HER2, antihuman EGFR type 2; NS, not significant; PD-L1, programmed death ligand-1.
of CLSPN inhibition on EGFR signaling was analyzed in the present study. The results indicated that the levels of phosphorylated Akt and Erk were lower in claspin siRNA2-and siRNA3-transfected ACHN cells than in control cells ( Figure 2B ).
| Analysis of the correlation between claspin expression and various cancer-related molecules
We revealed that claspin could contribute to tumor progression in RCC and that it was associated with the Akt and Erk pathways in EGFR downstream molecules. We thus next performed immunohistochemical analysis of various cancer-related molecules in 95 RCC cases. Of these 95 RCC cases, 27 (28%) were positive for CD44, 64 (67%) were positive for ALDH1, 12 (15%) were positive for CD133, 32 (34%) were positive for EGFR, 20 (21%)
were positive for HER2, 35 (37%) were positive for p53, and 33 (35%) were positive for PD-L1. Claspin expression was significantly associated with the expression of CD44 (P = .0002), EGFR (P = .0029), p53 (P = .0062), and PD-L1 (P = .0003; Table 3 ; Figure 3 ).
| D ISCUSS I ON
In the present study, we investigated the clinicopathological significance of claspin expression in RCC. The analysis of data in TCGA showed that claspin expression was upregulated in RCC tissues.
Our immunohistochemical analysis showed claspin expression was detected in 45 (47%) of 95 RCCs. Claspin staining appeared to be relatively stronger in high nuclear grade tumors than in low nuclear grade tumors. Moreover, claspin expression was associated with T grade, tumor stage, nuclear grade, vein invasion, and poor prognosis.
In addition, knockdown of CLSPN by RNAi was found to inhibit cancer cell proliferation and the levels of phosphorylated Akt and Erk.
Taken together, these results suggest that claspin serves an important role in the progression of RCC.
Cancer stem cells are thought to be responsible for recurrence or distant metastasis and for chemotherapy and radiotherapy resistance in many malignancies. 25 Cancer stem cells are frequently identified by surface protein markers such as CD44, CD105, CD133, ALDH1, and CXCR4 in RCC. 9, 26, 27 Among these surface markers, CD44 is the most frequently reported, and a positive correlation has been suggested with aggressive behavior in RCC. 28, 29 In fact, many studies have shown that CD44 expression was reported to significantly correlate with high nuclear grade, vein invasion, recurrence, and poor prognosis, and it has been suggested to be a useful prognostic marker. [29] [30] [31] [32] Moreover, CD44 promotes EGFR-mediated pathways, consequently leading to tumor cell growth, tumor cell migration, and chemotherapy resistance in solid cancers. 33 Therefore, as claspin expression in RCC was closely associated with CD44 expression in the present study, claspin might play an indispensable role in CSCs of RCC and might contribute to higher tumor stage, nuclear grade, and vein invasion in collaboration with CD44. In fact, overexpression of claspin increases resistance to radiotherapy and chemotherapy in lung and ovarian cancers. 19, 34, 35 Furthermore, we revealed that claspin expression was associated with p53 and poor prognosis. Similar to claspin, the tumor suppressor p53 is one of the key regulators in DNA damage response and the cell cycle checkpoint, and mutations of p53 have also been shown to lead to the generation of CSCs. 36, 37 In addition, several reports have shown that p53 expression in RCC predicts a poorer outcome. 38 A recent study reported that claspin is also a marker of prognosis in non-small-cell lung cancer. 35 Thus, these results indicate that claspin might be one of the potential prognostic factors in RCC.
CLSPN knockdown affects the levels of EGFR downstream molecules. We showed that the levels of phosphorylated Akt and Erk were lower in claspin siRNA-transfected RCC cells than in control cells. As the phosphorylation of Akt and Erk results in the inhibition of apoptosis and contributes to tumor progression, 39 these results suggest that apoptosis could be induced in claspin-knockdown RCC cells. Moreover, our results showed that claspin expression was frequently observed in EGFR-positive RCC cells by immunohistochemistry. Epidermal growth factor receptor plays a significant role in promoting tumor progression, and its associated signaling pathways are well established targets in cancer therapy. 40 Overexpression of EGFR in RCC is correlated with cell proliferation, high tumor stage, high nuclear grade, tumor recurrence, and overall survival. 41 PD-L1 and EGFR expression in RCC. 8 Therefore, the present study showed that claspin might be a promising molecule for treating RCC.
However, further extensive study will be required to elucidate the detailed molecular mechanism of its activity in tumor cell biology, which might improve our understanding of RCC carcinogenesis and tumor progression.
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